Counter-Regulatory Response to a Fall in Circulating Fatty Acid Levels in Rainbow Trout. Possible Involvement of the Hypothalamus-Pituitary-Interrenal Axis

Marta Librán-Pérez, Cristina Velasco, Marcos A. López-Patiño, Jesús M. Míquez, José L. Soengas*
Laboratorio de Fisiología Animal, Departamento de Biología Funcional e Ciencias de la Saúde, Facultade de Biología, Universidade de Vigo, Vigo, Spain

Abstract
We hypothesize that a decrease in circulating levels of fatty acid (FA) in rainbow trout *Oncorhynchus mykiss* would result in the inhibition of putative hypothalamic FA sensing systems with concomitant changes in the expression of orexigenic and anorexigenic factors ultimately leading to a stimulation of food intake. To assess this hypothesis, we lowered circulating FA levels treating fish with SDZ WAG 994 (SDZ), a selective A1 adenosine receptor agonist that inhibits lipolysis. In additional groups, we also evaluated if the presence of intralipid was able to counteract changes induced by SDZ treatment, and the possible involvement of the hypothalamic-pituitary-interrenal (HPI) axis by treating fish with SDZ in the presence of metyrapone, which decreases cortisol synthesis in fish. The decrease in circulating levels of FA in rainbow trout induced a clear increase in food intake that was associated with the decrease of the anorexigenic potential in hypothalamus (decreased POMC-A1 and CART mRNA abundance), and with changes in several parameters related to putative FA-sensing mechanisms in hypothalamus. Intralipid treatment counteracted these changes. SDZ treatment also induced increased cortisol levels and the activation of different components of the HPI axis whereas these changes disappeared in the presence of intralipid or metyrapone. These results suggest that the HPI axis is involved in a counter-regulatory response in rainbow trout to restore FA levels in plasma.

Citation: Librán-Pérez M, Velasco C, López-Patiño MA, Míquez JM, Soengas JL (2014) Counter-Regulatory Response to a Fall in Circulating Fatty Acid Levels in Rainbow Trout. Possible Involvement of the Hypothalamus-Pituitary-Interrenal Axis. PLoS ONE 9(11): e113291. doi:10.1371/journal.pone.0113291

Editor: Patrick Prunet, Institut National de la Recherche Agronomique (INRA), France

Received May 16, 2014; Accepted October 22, 2014; Published November 18, 2014

Copyright: © 2014 Librán-Pérez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.

Funding: Ministerio de Ciencia e Innovación and European Fund for Regional Development (AGL2013-46448-3-1-R and FEDER) to JLS. Xunta de Galicia (Consolidación e estruturación de unidades de investigación competitivas do sistema universitario de Galicia, CN 2012/004) to JLS. Ministerio de Ciencia e Innovación (Predoctoral Fellowship, Program FPI) to MLP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: jssoengas@uvigo.es

Introduction

Specialized neurons within mammalian hypothalamus have been suggested to detect increases in plasma levels of long-chain fatty acid (LCFA), but not short-chain (SCFA) or medium-chain (MCFA) FA through several mechanisms [1,2,3], such as i) FA metabolism through inhibition of carnitine palmitoyltransferase 1 (CPT-1) to import FA-CoA into the mitochondria for oxidation; ii) binding to FA translocase (FAT/CD36), and further modulation of transcription factors like peroxisome proliferator-activated receptor type α (PPARα), and sterol regulatory element-binding protein type 1c (SREBP1c); iii) activation of protein kinase C-β; and iv) mitochondrial production of reactive oxygen species (ROS) by electron leakage resulting in an inhibition of ATP-dependent inward rectifier potassium channel (K<sub>ATP</sub>) activity. Changes in these systems have been associated [4] with the modulation of hypothalamic homeobox domain transcription factor (BSX), forkhead box 01 (FoxO1), and phosphorylated cAMP response-element binding protein (pCREB). The action of these factors would result in the inhibition of the orexigenic factors agouti-related protein (AgRP) and neuropeptide Y (NPY), and the enhancement of the anorexigenic factors pro-opio melanocortin (POMC) and cocaine and amphetamine-related transcript (CART) ultimately leading to decreased food intake [1,4].

In fish, a reduced food intake has been observed after feeding fish with lipid-enriched diets or in fish containing high fat stores [5,6,7,8,9,10,11] raising the question whether lipid sensing mechanisms regulating food intake may be also present in fish [12,13]. Accordingly, we observed in rainbow trout *Oncorhynchus mykiss* that intraperitoneal [14] or intracerebroventricular [15] administration of oleate (LCFA) or octanoate (MCFA) elicited an inhibition in food intake. Furthermore, the treatment induced a response in the hypothalamus compatible with FA sensing including reduced potential of lipogenesis and FA oxidation, decreased potential of K<sub>ATP</sub>, and modulation of FAT/CD36 with subsequent changes in the expression of transcription factors [14,15,16]. This response is comparable in general with that reported in mammals with the main difference of the capacity of fish to respond to increased levels of an MCFA like octanoate [15]. Changes in these hypothalamic pathways can be also related to the control of food intake, since changes in mRNA levels of neuropeptides such as NPY and POMC-A1 were also noted [14,15,16]. In the hypothalamus of another fish species, the orange-spotted grouper (*Epinephelus coioides*), the involvement of...
FA metabolism and mitochondrial activity in the orexigenic effects of NPY has been also suggested [17].

The fall of blood glucose levels is sensed in central glucosensor areas eliciting counter-regulatory responses to restore glucose levels as demonstrated in mammals [18] and fish [19,20]. This mechanism has been evidenced in rat for metabolites other than glucose, such as FA. Thus, the counter-regulatory response to decreased circulating levels of FA has been associated with the activation of the hypothalamus-pituitary-adrenal (HPA) axis, and, therefore, to enhanced circulating levels of glucocorticoids whose lipolytic action would restore plasma FA levels [21,22,23]. In fish fed with diets containing low lipid levels, an increase in food intake has been described [6,8,9,10,24,25] but to date there is no evidence available regarding the existence of counter-regulatory responses to decreased FA levels. We hypothesize that the decrease in circulating levels of FA in rainbow trout would result in the down-regulation of putative hypothalamic FA sensing systems [13] with concomitant changes in the expression of orexigenic and anorexigenic factors ultimately leading to a stimulation of food intake. To assess this hypothesis, we lowered circulating FA levels in rainbow trout feeding with SDZ WAG 994 (SDZ), a selective A1 adenosine receptor agonist that inhibits lipolysis [26]. We also evaluated if the presence of intralipid (a lipid emulsion of phospholipid-stabilized soybean oil for intravenous administration, Sigma Chemical Co) was able to counteract changes induced by SDZ treatment. Furthermore, we also evaluated the possible involvement of the hypothalamus-pituitary-interrenal (HPI) axis (fish equivalent to mammalian HPA) in the counter-regulatory response. Thus, we modified an accessible part of the HPI axis such as cortisol levels by treating fish with SDZ in the presence of metyrapone, which decreases cortisol synthesis in fish [27,28].

Materials and Methods

Ethics statement
The experiments described comply with the Guidelines of the European Union Council [2010/63/UE], and of the Spanish Government (RD 55/2013) for the use of animals in research. The Ethics Committee of the Universidade de Vigo approved the procedures.

Fish
Rainbow trout obtained from a local fish farm (A Estrada, Spain) were maintained for 1 month in 100 litre tanks under laboratory conditions and 12L:12D photoperiod in dechlorinated tap water at 15°C. Fish weight was 99±3 g. Fish were fed once daily (09.00 h) to satiety with commercial dry fish pellets (Dibaq-Diproteg SA, Spain).

Experimental design
Following acclimation, fish were fasted for 24 h before treatment to ensure fish had basal levels of metabolic hormones including cortisol. On the day of experiment, a first set of fish were anaesthetized in tanks with 2-phenoxyethanol (Sigma, 0.2% v/v), and weighed. Then, 15 fish per group received intraperitoneally (IP) 10 mLg⁻¹ injection of saline solution alone (control, C), or containing SDZ (SDZ; Tocris, 60 μgKg⁻¹), metyrapone (M; Sigma, 1 mgKg⁻¹), both SDZ and metyrapone (SDZ+M), or both SDZ and intralipid (SDZ+IL; Sigma I-141, 3 mLKg⁻¹).

Blood, hypothalamus, and head kidney samples were withdrawn, dried and weighed. The amount of food consumed by all fish in each tank was calculated as previously described [31,32,33]. Results are shown as the mean ± SEM of the data obtained in three different tanks per treatment.

Assessment of metabolite levels and enzyme activities
Levels of FA, total lipid, triglyceride, glucose, and lactate in plasma were determined enzymatically using commercial kits (Wako for FA; Spinresect for total lipid, triglyceride, and lactate; Biomerieux for glucose) adapted to a microplate format. Plasma cortisol levels were assessed by ELISA using a commercially available kit (Cayman).

Samples used to assess hypothalamic metabolite levels were homogenized immediately by ultrasonic disruption in 7.5 vols of ice-cooled 0.6 M perchloric acid, and neutralized (using 1 M potassium bicarbonate). The homogenate was centrifuged (10,000 g), and the supernatant used to assay tissue metabolites. Tissue FA, total lipid, and triglyceride levels were determined enzymatically using commercial kits as described above for plasma samples.

Samples for enzyme activities were homogenized by ultrasonic disruption with 9 vols of ice-cold buffer consisting of 50 mM Tris (pH 7.6), 5 mM EDTA, 2 mM 1,4-dithiothreitol, and a protease inhibitor cocktail (Sigma). The homogenate was centrifuged (10,000 g) and the supernatant used immediately for enzyme assays. Enzyme activities were determined using a microplate reader INFINITE 200 Pro (Tecan) and microplates. Reaction rates of enzymes were determined by the increase or decrease in absorbance of NAD(P)/H at 340 nm or, in the case of CPT-1 activity, of 5,5′-Dithiobis(2-nitrobenzoyl)acid-CoA (DTNB) complex at 412 nm. The reactions were started by the addition of supernatant (15 μl) at a pre-established protein concentration, omitting the substrate in control wells (final volume 265–295 μl), and allowing the reactions to proceed at 20°C for pre-established times (3–10 min). Enzyme activities are expressed per protein level, which was assayed according to the bicinchoninic acid method with bovine serum albumin (Sigma) as standard. Enzyme activities were assessed at maximum rates determined by preliminary tests to determine optimal substrate concentrations. ATP-citrate lyase (ACLY, EC 4.1.3.8) activity was assessed in a
Table 1. Nucleotide sequences of the PCR primers used to evaluate mRNA abundance by RT-PCR (qPCR).

| Forward primer | Reverse primer | Data base | Accession Number |
|----------------|----------------|-----------|-----------------|
| 3β-HSD         | TCACAGCTTGGATCAAGGAG    | GenBank  | S72665.1        |
| 11β-HSD        | ATCCCGCCGAGACACAGAGGCGAG | GenBank  | AF178994        |
| ACC            | TGGGCCTCCCTCACTCCATCC  | Sigena   | tcbb00100c.b21.5.1.om.4 |
| ACYL-βCoA      | CTGAGGCCAGCCGAGAGGAG   | GenBank  | CA3494311.1     |
| CART           | GGCACCTGGTCTCCTCAAG    | GenBank  | NM_0011246622   |
| CPT-1c         | CGGTCTCAAGTGGACTCTTCA  | GenBank  | A619768         |
| CPT-1d         | ACATCTGGACTGATCATGCT   | GenBank  | A620356         |
| CRF            | AACCATGTTGCTCGACTGCT   | GenBank  | AF209672        |
| CRFBBP         | GGAGGAGCTTCCTCAAGGTTGTC | GenBank  | AY363677        |
| CS             | GGCCAGATGGCTGAGGTTCA   | Tigr     | TC89195         |
| EF-1x          | TCCTCTCTGTCGCTTTGCTG   | GenBank  | AF498320        |
| FAS            | GACCATCTGGAGGAGGTTGCT  | Sigena   | tca00011.e.06.5.1.om.8 |
| FAT/CD36       | AAGGTTGAGCTGACTGCTG    | GenBank  | CA3462611.s.om.8:1.773:1 |
| Kir6.1x-like   | TTGGCTCTGCTGCCCTGTT    | Sigena   | CA3462611.s.om.8:1.773:1 |
| LXRα           | TGGCGAGGCTGTATGGA      | GenBank  | FJ470291        |
| MCD            | TCACAGCTTGGAGGAGGTTG   | Sigena   | BXY69708.8:s.10 |
| NPY            | GGCACCTGGATCATGCTGTA   | GenBank  | NM_001124666    |
| P450sc         | ATGCTGTCACCTACCTACACCA| GenBank  | S57305.1        |
| POMC-A1        | TCCTGGCTGACCTACCTACCT  | GenBank  | CA0849441.1     |
| PPARαx         | GCAAGGAGTGGTCCCTGCTG   | GenBank  | AB047032        |
| SREBP1c        | CACAGCTTACCATGACACACAG| GenBank  | AY380435        |
| SUR-like       | CGAGGACTGGCCCCCAGA     | Sigena   | tce0019d.e.20.3.1.s.om.8 |
| UCP2a          | TCCGGCTACGACTCCAGG     | GenBank  | DQ295324        |

3β-HSD, 3β-hydroxysteroid dehydrogenase; 11β-HSD, 11β-hydroxysteroid dehydrogenase; ACC, Acetyl-CoA carboxylase; ACLY, ATP-citrate lyase; CART, cocaine- and amphetamine-related transcript; CPT-1, carnitine palmitoyl transferase type 1; CRF, corticotropin releasing factor; CRFBBP, corticotropin releasing factor binding protein; CS, citrate synthetase; EF-1α, elongation factor 1α; FAS, fatty acid synthetase; FAT/CD36, fatty acid translocase; Kir6.1x-like, inward rectifier K⁺ channel pore type 6.x-like; LXRα, liver X receptor α; MCD, malonyl CoA dehydrogenase; NPY, neuropeptide Y; P450sc, cytochrome P450 cholesterol side chain cleavage; POMC-A1, pro-opio melanocortin A1; PPARαx, peroxisome proliferator-activated receptor type α; SREBP1c, sterol regulatory element-binding protein type 1c; STAR, steroidogenic acute regulatory protein; SUR-like, sulfonylurea receptor-like; UCP2a, mitochondrial uncoupling protein 2a.

mRNA abundance analysis by quantitative RT-PCR

Total RNA extracted from tissues using Trizol reagent (Life Technologies) was treated with RQ1-DNase (Promega). 4 μg total RNA were reverse transcribed into cDNA using Superscript II reverse transcriptase (Promega) and random hexamers (Promega). Gene expression levels were determined by real-time quantitative RT-PCR (q-PCR) using the iCycler IQ (BIO-RAD). Analyses were performed on 1 μl cDNA using the MAXIMA SYBRGreen qPCR Mastermix (Thermo Fisher Scientific), in a total PCR reaction volume of 25 μl, containing 50–500 nM of each primer. mRNA abundance of transcripts 3β-hydroxysteroid dehydrogenase (3βHSD), 11β-hydroxylase (11βH), acetyl-CoA carboxylase (ACC), ACLY, CART, corticotropin releasing factor (CRF), corticotropin releasing factor binding protein (CRFBBP), FAT/CD36, CPT-1, citrate synthetase (CS), FAS, inward rectifier K⁺ channel pore type 6.x-like (Kir6.1x-like), liver X receptor α (LXRα), malonyl-CoA dehydrogenase (MCD), NPY, cytochrome P450 cholesterol side chain cleavage (P450sc), POMC-A1, PPARαx, SREBP1c, sterol regulatory element-binding protein type 1c (STAR), steroidogenic acute regulatory protein (SUR-like), sulfonylurea receptor-like (SUR-like), and mitochondrial uncoupling protein 2a (UCP2a), was determined as previously described in the same species [35,36,37,38,39,40,41,42,43,44,45]. Sequences of the forward and reverse primers used for each gene expression are shown in Table 1. Relative quantification of the target gene transcripts was done using elongation factor 1α (EF-1α) gene expression as reference, which was stably expressed in this experiment.

Thermal cycling was initiated with incubation at 95°C for 15 s using hot-start iTaq DNA polymerase activation; 40 steps of PCR were performed, each one consisting of heating at 95°C for 15 s for denaturing, annealing at specific temperatures for 30 s,
and extension at 72°C for 30 s. Following the final PCR cycle, melting curves were systematically monitored (55°C temperature gradient from 55 to 95°C) to ensure amplification of only one fragment. Each sample was assessed in triplicate. Samples without reverse transcriptase and samples without RNA were run for each reaction as negative controls. Only efficiency values between 85–100% were accepted (the R² for all the genes assessed was always higher than 0.985). Relative quantification of the target gene transcript with the EF-1α transcript was made following the Pfaffl method [46].

Statistics

Comparisons among groups were carried out with two-way ANOVA with treatment and time as main factors for food intake data whereas the remaining parameters were compared with one-way ANOVA. Post-hoc comparisons were carried out with a Student-Newman-Keuls test, and differences were considered statistically significant at P<0.05.

Results

Food intake increased after 6 and 24 h of treatment with SDZ, and the presence of intralipid counteracted the increase (Fig. 1).

Levels of metabolites assessed in plasma are shown in Fig. 2. FA (Fig. 2A) and triglyceride (Fig. 2B) levels decreased after SDZ treatment compared with all other groups. Total lipid levels (Fig. 2C) decreased after treatment with SDZ or SDZ +IL compared with the remaining groups, and the decrease was weaker in the SDZ +IL group. Glucose levels increased after treatment with SDZ +M compared with control and SDZ groups (Fig. 2D). Lactate levels increased after SDZ +IL treatment compared with SDZ +M (Fig. 2E). Cortisol levels were higher in the SDZ group than in all other groups (Fig. 2F).

In hypothalamus (Fig. 3) SDZ treatment decreased levels of FA (vs. all other groups) and triglycerides (vs. control, SDZ +M and SDZ +IL groups) whereas no significant changes were noted for total lipid levels.

Enzyme activities assessed in hypothalamus are shown in Fig. 4. FAS activity was lower in the SDZ and M groups compared with the remaining groups (Fig. 4B). HOAD activity was lower in the SDZ group than in control, SDZ +M, and SDZ +IL groups (Fig. 4D). We did not observe significant differences for CPT-1 (Fig. 4A) and ACLY (Fig. 4C) activities.

RNA abundance of transcripts related to fatty acid sensing in hypothalamus is shown in Table 2. FAT/CD36 level was lower in the SDZ group compared with control, M, and SDZ +IL groups. ACC level increased in the M group compared with control, SDZ +M, and SDZ +IL groups. ACLY level increased after M treatment compared with control, SDZ, and SDZ +IL treatments. CPT-1c level decreased in the SDZ group compared with control and SDZ +IL groups. Levels of CPT-1d in the SDZ group were lower than in control, M, and SDZ +IL groups. FAS level increased in the group treated with SDZ compared with all other groups. MCD values were lower in the SDZ group than in control and SDZ +IL groups. UCP2a values were higher in the SDZ group than in control, SDZ +M, and SDZ +IL groups whereas those of SDZ +IL group were lower than in all other groups. The level of SUR-like was lower in the M and SDZ +M groups than in all other groups. PPARα level increased after treatment with M or SDZ +M compared with all other groups. CART level decreased after treatment with SDZ or SDZ +M compared with control and SDZ +IL groups. POMC-A1 level decreased after treatment with SDZ or SDZ +M compared with control and SDZ +IL groups with the decrease being more important for SDZ +M; the value of SDZ +IL was higher than in all other groups. Finally, no
significant changes were apparent for CS, Kir6.x-like, LXRα, and NPY.

RNA abundance of transcripts related to HPI axis in hypothalamus and head kidney is shown in Table 3. In hypothalamus, CRF value was higher in the SDZ group compared with all other groups whereas value of SDZ + IL group was higher than in M and SDZ + M groups. CRFBP levels increased after treatment with SDZ or M compared with control, SDZ + M, and SDZ + IL groups. 3βHSD level increased after treatment with SDZ compared with all other groups; values in the SDZ + M group were lower than in all other groups. 11βH level increased after treatment with SDZ or M compared with all other groups with the increase being higher for M group, and decreased after treatment with SDZ + M compared with all other groups. P450scc level increased in the group treated with SDZ compared with the remaining groups; the level in the M and SDZ + M groups was lower than in all other groups with the decrease being more important for SDZ + M. Finally, StAR value increased after treatment with SDZ compared with all other groups.

**Discussion**

Lowering circulating FA levels in rainbow trout decreased anorexigenic potential in hypothalamus and increased food intake

Treatment with SDZ was effective in reducing not only circulating FA levels but also those of triglyceride and total lipid, which validates the experimental design. These changes are similar to those reported in rat after similar treatment [22,29,47]. There are no comparable references available in fish, though in zebrafish bezafibrate treatment was also able to decrease plasma triglyceride and cholesterol levels [48]. Moreover, the presence of intralipid was able to counteract the action of SDZ in rainbow trout resulting in levels of FA and triglyceride similar to those of controls, again in agreement with that reported in rat [22].

Food intake increased in fish treated with SDZ. This allows us to suggest, for the first time in fish, that hypothalamus sense the decreased levels of FA resulting in an orexigenic response stimulating food intake. We cannot exclude the possibility that SDZ could have a direct effect on food intake independent of that elicited by the inhibition of lipolysis. However, the finding that the presence of intralipid counteracted the increased food intake suggest that the effect of reduced FA levels is more likely. This increased food intake is in agreement with that reported in different fish species, including rainbow trout, after feeding diets with low lipid content [6,8,9,10,24,25]. Furthermore, the food intake response is the opposite of that observed when the same species was treated with specific FA such as oleate or octanoate [14]. Changes elicited in the levels of circulating lipids relate to changes observed in hypothalamus since SDZ treatment decreased levels of FA and triglyceride, and levels recovered those of controls after additional treatment with intralipid. Therefore, changes in circulating metabolites in plasma are translated into changes in
metabolite levels in hypothalamus thus supporting the FA sensing capacity of that tissue not only to increased levels of FA as previously described [14,15,16] but also to decreased levels of circulating FA as herein reported. Accordingly, we evaluated changes in parameters related to putative FA sensing systems in hypothalamus in order to relate them to changes observed in food intake.

SDZ treatment affected the FA sensing system related to FA metabolism since it decreased the activity of FAS and HOAD as well as mRNA abundance of CPT1c, CPT1d, and MCD and increased mRNA abundance of FAS. Furthermore, the presence of intralipid counteracted these changes. We have previously observed that this system responds to increased levels of FA with decreased lipogenic potential and decreased capacity of FA oxidation [14,15,16]. Therefore, we expected that changes observed in parameters related to FA metabolism would be different than those observed after increasing levels of specific FA such as oleate or octanoate [14]. Accordingly, we observed opposite changes for FAS activity and mRNA abundance as well as for mRNA abundance of CPT1c and MCD. However, other parameters that displayed changes in situations of increased circulating levels of oleate or octanoate [14,15,16] such as CPT1 and ACLY activities and mRNA abundance of ACC, ACLY, and CS did not display any change in the present study. The responses observed suggest that the FA sensing system related to FA metabolism only respond partially to decreased circulating levels of FA. There are no similar studies available in fish hypothalamus [13] whereas in peripheral tissues like liver lipogenic potential is up-regulated when fish were fed with diets with low lipid content [49].

The putative FA sensing system related to FA transport through FAT/CD36 and subsequent modulation of transcription factors partially responded to decreased circulating levels of FA since several parameters did not show changes compared with controls (mRNA abundance of PPARα, SREBP1c, and LXRα). Only mRNA abundance of FAT/CD36 decreased after SDZ treatment. This change is the opposite of that previously observed when FA levels increased [14] suggesting a decreased potential for binding capacity of FAT/CD36 in parallel with the decreased circulating FA levels.

As for the putative FA sensing system related to KATP channel and mitochondrial activity, Kir6.1-x-like and SUR-like mRNA abundance displayed no changes when circulating FA levels decreased. However, levels of UCP2a mRNA were higher in the group treated with SDZ than in controls, a change opposite of that described when FA levels increased [14,15].

Despite the relatively few changes observed in the FA sensing systems evaluated, mRNA abundance of anorexigenic peptides (POMC-A1 and CART) clearly decreased in hypothalamus of fish treated with SDZ. This response is the opposite of that observed under conditions of increased circulating FA levels where the abundance of these transcripts increased [13]. Moreover, the increase observed in the mRNA abundance of POMC-A1 in the SDZ+IL group could be associated with the returning of food intake in that group to values similar of those in control group. Furthermore, we did not observe significant changes in NPY mRNA abundance when FA levels decreased, in contrast with the decrease observed when FA levels increased [14,15]. These changes suggest a decreased anorexigenic potential in hypothalamus of SDZ-treated fish, which is in agreement with changes noted in food intake. However, CRF mRNA levels increased under the same conditions what considering the anorexigenic nature of this peptide suggest a more complex relationship between changes in mRNA levels of neuropeptides and food intake.

Therefore, it seems that the decrease in circulating FA levels induced by SDZ treatment resulted in decreased levels of FA in hypothalamus but only few of the parameters involved in putative FA sensing systems addressed in hypothalamus changed accordingly. However, since the expression of several neuropeptides and, more important, food intake changed under those conditions, we can suggest, for the first time in non-mammalian vertebrates, that central capacity for sensing decreased FA levels exists in fish. However, this modulation of FA sensors is not exactly the opposite of that observed when FA levels increase [14,15,16]. The difference in the response of these systems to increased or decreased FA levels could be due to different factors. Any of these factors could be: i) the involvement of another putative FA sensing mechanism, such as that mediated by PKC-θ [2], or ii) the fact that we evaluated the decrease of FA in general whereas in the other studies carried out in rainbow trout [14,15,16] we evaluated the increase of specific FA, such as oleate and octanooate. In fact, in...
Among treatment.

Solution (SDZ)

Trout after 6 h of intraperitoneal administration of 10 mL.Kg$^{-1}$

FA counter-regulatory response to decreased levels of FA.

The activation of the HPI axis is probably involved in the FA counter-regulatory response to decreased levels of FA.

In mammals, different hormones of lipolytic action such as growth hormone [50], epinephrine [51], glucagon [52] or glucocorticoids [21,22,23] were associated with the counter-regulatory response to decreased levels of FA. In the present study, we have evaluated the possibility that cortisol (main glucocorticoid in fish) could be involved in the counter-regulatory response observed in rainbow trout.

SDZ treatment induced an increase in circulating levels of cortisol, which was not observed in the SDZ+IL group. This allows us to suggest that the activation of the HPI axis is involved in the response to decreased levels of FA. This response is comparable to that observed in rat where the presence of intralipid also counteracted the decrease in circulating FA levels induced by SDZ treatment [22]. We have also monitored in head kidney the mRNA abundance of proteins involved in cortisol synthesis such as 11βH, 3βHSD, P450scc and StAR. Abundance of these transcripts increased after treatment with SDZ, and values returned to normality when fish were co-treated with SDZ and intralipid. In rainbow trout up-regulation of these transcripts corresponds with enhanced cortisol levels in plasma [53,54]. Therefore, changes observed in these transcripts agree well with those of cortisol levels. Furthermore, we have also monitored hypothalamic CRF and CRFBP mRNA abundance that in the same species are normally changing in parallel with the levels of cortisol in plasma under short-term periods [55]. SDZ treatment increased levels of both transcripts and, once more, the presence of intralipid counteracted such elevation. Interestingly, an inverse relationship between plasma glucose and FA was observed in plasma in agreement with that seen in many fish species under stress situations in which the HPI axis is activated [56]. Altogether, these results suggest that decreased circulating levels of FA activate the HPI axis. However, we cannot discard a direct action of SDZ on cortisol synthesis.

Further support of the involvement of the HPI axis comes from results obtained in the groups treated with metyrapone. Metyrapone is an inhibitor of 11βH, and its treatment resulted in decreased circulating levels of cortisol in previously stressed fish [27,28,30] or no changes if fish were not previously stressed [57,58], as observed in the present study. A glucocorticoid feedback response (i.e., increased CRF mRNA levels in response to decreased cortisol levels) has been demonstrated in rainbow trout when plasma cortisol levels changed after metyrapone treatment [27,59]. Thus, the lack of changes in cortisol levels in the M group is also reflected by the absence of changes in hypothalamic CRF mRNA levels. Changes observed in hypothalamus of metyrapone-treated fish (up-regulation of ACC, ACLY and PPAR$x$ mRNA abundance) generally fit with those previously observed in catfish brain [58] where increased lipogenic capacity occurred after metyrapone treatment. However, since metyrapone treatment alone induced changes in several parameters assessed in hypothalamus and head kidney, we cannot discard that several of the effects could be attributable to an interactions between SDZ and metyrapone.

Based on the comparison between SDZ and SDZ+M groups, metyrapone treatment was effective in counteracting the increased cortisol levels elicited by SDZ treatment. This effect of metyrapone is in agreement with that previously observed in the same species under different stressful conditions [27,28,30]. Furthermore, the treatment with both metyrapone and SDZ induced in plasma changes in parameters in a way that values were comparable to those of the control group and different than those of the SDZ group, such as for plasma FA, triglyceride or total lipid levels. This return to normality is also evident in parameters assessed in hypothalamus where FA and triglyceride levels that decreased in the SDZ group turned back to normal values in the group treated with SDZ and metyrapone. In parameters related to the HPI axis, an effective blockade of its functioning was apparent as demonstrated by the strong decrease observed in transcript abundance of the four proteins related to cortisol metabolism.

Figure 4. Changes in the activity of enzymes in hypothalamus after intraperitoneal treatment. Activities (mU.mg$^{-1}$ protein) of CPT-1 (A), FAS (B), ACLY (C), and HOAD (D) in hypothalamus of rainbow trout after 6 h of intraperitoneal administration of 10 mL.Kg$^{-1}$ of saline solution alone (control, C) or containing SDZ WAG 994 (SDZ, 60 μg.Kg$^{-1}$), metyrapone (M, 1 mg.Kg$^{-1}$), both SDZ WAG 994 and metyrapone (SDZ+M), or both SDZ WAG 994 and intralipid (3 mL.Kg$^{-1}$) solution (SDZ+IL). The results are shown as mean±S.E.M. of 10 fish per treatment. Different letters indicate significant differences (P<0.05) among treatment.

doi:10.1371/journal.pone.0113291.g004

A recent study in rat, the counter-regulatory response to decreased FA levels depends on the type of FA [23].

The activation of the HPI axis is probably involved in the FA counter-regulatory response to decreased levels of FA.
assessed in head kidney in the SDZ+metyrapone group. These changes are associated with those observed in the levels of cortisol in plasma, which were similar to those of the control group and lower than in the SDZ-treated group. Further support comes from changes observed in CRF and CRFBP mRNA abundance in the hypothalamus where a significant inhibition of the response

Table 2. Relative mRNA abundance of transcripts related to fatty acid sensing in hypothalamus of rainbow trout after 6 h of intraperitoneal administration of 10 mL.Kg⁻¹ of saline solution alone (control, C) or containing SDZ WAG 994 (SDZ, 60 μg.Kg⁻¹), metyrapone (M, 1 mg.Kg⁻¹), both SDZ WAG 994 and metyrapone (SDZ+M), or both SDZ WAG 994 and intralipid (3 mL.Kg⁻¹) solution (SDZ+IL).

|                     | C       | SDZ     | M       | SDZ+M   | SDZ+IL  |
|---------------------|---------|---------|---------|---------|---------|
| **Fatty acid transport** |         |         |         |         |         |
| FAT/CD36            | 1.05a   | 0.63±0.04b | 1.13±0.09a | 0.89±0.12ab | 1.23±0.08a |
| **Fatty acid metabolism** |         |         |         |         |         |
| ACC                 | 1.16a   | 1.15±0.12ab | 1.80±0.25b | 0.99±0.08a | 1.06±0.16a |
| ACLY                | 1.11a   | 1.07±0.11a  | 1.70±0.14b | 1.30±0.20ab | 0.99±0.14a |
| CPT-1c              | 1.08a   | 0.62±0.05b | 0.90±0.09ab | 0.69±0.10ab | 1.15±0.11a |
| CPT-1d              | 0.06ab  | 0.57±0.04c | 0.96±0.12ab | 0.64±0.08bc | 1.24±0.11a |
| CS                  | 1±0.16  | 0.88±0.12  | 1.46±0.20  | 0.93±0.16  | 1.15±0.12 |
| FAS                 | 1±0.08a | 1.58±0.09b | 1.17±0.12a | 1.16±0.09a | 1.14±0.13a |
| MCD                 | 1±0.08a | 0.57±0.06b | 0.75±0.13ab | 0.72±0.05ab | 1.43±0.23a |
| **Mitochondrial uncoupling** |         |         |         |         |         |
| UCP2a               | 1±0.12a | 1.51±0.10b | 1.34±0.14a | 0.82±0.14a | 0.47±0.07c |
| **K⁺ channel**      |         |         |         |         |         |
| Kir6.x-like         | 1±0.13  | 0.98±0.08  | 0.92±0.11  | 0.86±0.09  | 1.40±0.21 |
| SUR-like            | 1±0.12a | 0.81±0.07a | 0.58±0.07b | 0.49±0.03b | 1.03±0.10a |
| **Transcription factors** |         |         |         |         |         |
| LXRx                | 1±0.13  | 0.73±0.06  | 1.22±0.16  | 0.86±0.09  | 1.03±0.12 |
| PPARα               | 1±0.15a | 1.02±0.13a | 2.39±0.18b | 1.88±0.14b | 1.26±0.16a |
| SREBP1c             | 1±0.11  | 0.96±0.11  | 1.31±0.15  | 0.90±0.09  | 1.32±0.12 |
| **Neuropeptides**   |         |         |         |         |         |
| CART                | 1±0.11a | 0.53±0.13b | 0.75±0.05ab | 0.57±0.08b | 1.13±0.11a |
| NPY                 | 1±0.07  | 1.09±0.09  | 1.28±0.15  | 1.06±0.09  | 1.03±0.12 |
| POMC-A1             | 1±0.06a | 0.54±0.05b | 0.75±0.08ab | 0.37±0.06b | 2.50±0.22c |

Data represent mean of 5 measurements. Data is expressed with respect to the control group (expression results were normalized by EF-1α mRNA levels, which did not show changes among groups). Different letters indicate significant differences (P<0.05) among treatments.

doi:10.1371/journal.pone.0113291.t002

Table 3. Relative mRNA abundance of transcripts related to hypothalamus-pituitary-interrenal axis in hypothalamus and head kidney of rainbow trout after 6 h of intraperitoneal administration of 10 mL.Kg⁻¹ of saline solution alone (control, C) or containing SDZ WAG 994 (SDZ, 60 μg.Kg⁻¹), metyrapone (M, 1 mg.Kg⁻¹), both SDZ WAG 994 and metyrapone (SDZ+M), or both SDZ WAG 994 and intralipid (3 mL.Kg⁻¹) solution (SDZ+IL).

|                     | C       | SDZ     | M       | SDZ+M   | SDZ+IL  |
|---------------------|---------|---------|---------|---------|---------|
| **Hypothalamus**    |         |         |         |         |         |
| CRF                 | 1±0.11a | 1.74±0.10b | 0.69±0.09a | 0.63±0.07a | 1.19±0.11a |
| CRFBP               | 1±0.09a | 1.49±0.07b | 1.88±0.17b | 1.35±0.10a | 1.01±0.12a |
| **Head kidney**     |         |         |         |         |         |
| 3IHS                 | 1±0.17a | 1.77±0.12b | 1.30±0.15a | 0.32±0.03c | 0.86±0.14a |
| 1IβH                 | 1±0.13a | 1.91±0.14b | 3.17±0.33c | 0.31±0.09d | 1.28±0.20a |
| P450cc               | 1±0.15a | 1.68±0.07b | 0.52±0.11c | 0.08±0.01d | 1.08±0.15a |
| STAR                 | 1±0.18a | 1.92±0.13  | 1.23±0.10a | 0.77±0.09a | 1.26±0.11a |

Data represent mean of 5 measurements. Data is expressed with respect to the control group (expression results were normalized by EF-1α mRNA levels, which did not show changes among groups). Different letters indicate significant differences (P<0.05) among treatments.

doi:10.1371/journal.pone.0113291.t003
Regulatory Response to Decreased Fatty Acid Levels in Trout

Conclusions

In summary, we have obtained evidence, for the first time in fish (and in a non-mammalian vertebrate), about the existence of a counter-regulatory response to a fall in circulating FA levels. The response is apparently associated with food intake control and the activation of HPI axis. Thus, the decrease in circulating levels of FA in rainbow trout induces an increase in food intake that is associated with the decrease of the anorexigenic potential in hypothalamus and with changes in several parameters related to putative FA-sensing mechanisms in hypothalamus. The treatment with intralipid counteracted these changes. The decrease in FA levels apparently induces a counter-regulatory response in rainbow trout in which the activation of the HPI axis is likely involved. This activation probably not related to the control of food intake through FA sensor systems [13] but to the modulation of lipolysis in peripheral tissues to restore FA levels in plasma. This counter-regulatory response initiated in the hypothalamus, probably through changes in CRF, and this activation would arrive to peripheral tissues such as liver where metabolic changes would occur accordingly. However, we cannot exclude the possibility that i) the fall in plasma FA was sensed outside the brain, and the information be transmitted via an afferent neural pathway or a humoral factor, or ii) that other lipolytic hormones in fish such as GH, glucagon or catecholamines [63,64,65,66,67] could be involved in the FA counter-regulatory response. All these possibilities clearly deserve further studies.

Author Contributions

Conceived and designed the experiments: JMM JLS. Performed the experiments: MLP CV MALP JMM JLS. Analyzed the data: MLP CV MALP JMM JLS. Contributed reagents/materials/analysis tools: MALP JMM JLS. Contributed to the writing of the manuscript: MLP CV MALP JMM JLS.

References

1. López M, Lefebvre CJ, Vidal-Puig A (2007) Hypothalamic fatty acid metabolism: a housekeeping pathway that regulates food intake. BioEssays 29: 248–261.
2. Benoit SC, Kemp CJ, Eltis CF, Alphanap W, Herman JP, et al. (2009) Palmitic acid mediates hypothalamic insulin resistance by altering PKC-0 subcellular localization in rodents. J Clin Invest 119: 2577–2590.
3. Blouet C, Schwartz GJ (2010) Hypothalamic nutrient sensing in the control of energy homeostasis. Behav Brain Res 209: 1–12.
4. Diéguez C, Vazquez MJ, Rosnero A, López M, Nogueiras R (2011) Hypothalamic control of lipid metabolism: focus on leptin, ghrelin and melanocortins. Neuroendocrinology 94: 1–11.
5. Shearer KD, Silverstein J, Platskaya EM (1997) Role of adiposity in food intake control of juvenile chinook salmon (Oncorhynchus tshawytscha). Comp Biochem Physiol A 118: 1209–1215.
6. Silverstein JT, Shearer KD, Dickhoff WW, Platskaya EM (1999) Regulation of nutrient intake and energy balance in salmon. Aquaculture 177: 161–169.
7. Rasmussen RS, Ostenfeld TH, Roenshold B, McLean E (2000) Manipulation of dietary lipid level and voluntary feed intake, growth, nutrient gain, lipid deposition and hepatic lipogenesis in rainbow trout. Reprod Nutr Dev 41: 487–503.
8. Johansen SJS, Elki M, Jøhblom M (2002) Is there leptinostatic regulation of feed intake in Atlantic salmon Salmo salar L? Aquaculture 33: 513–524.
9. Johansen SJS, Swier H, Jøhblom M (2005) Lipostatic regulation of feed intake in Atlantic salmon Salmo salar L. defending adiposity at the expense of growth. Aquaculture 35: 317–331.
10. Figueiredo-Silva AC, Kaushik S, Terrier F, Schrama JW, Mérédé F, et al. (2012) Link between lipid metabolism and voluntary food intake in rainbow trout fed coconut oil rich in medium-chain TAG. Br J Nutr 107: 1714–1725.
11. FrØiland E, Jobling M, Bjoñrnsson BT, Kling P, Ravuri CS, et al. (2012) Evidence of a metabolic fatty-acid sensing system in the hypothalamus and Brockmann bodies of rainbow trout: implications in food intake regulation. Am J Physiol Regul Integr Comp Physiol 302: R1340–R1350.
12. Schrama JW, Saravanan S, Geurden I, Heinsbroek LTN, Kaushik S, et al. (2002) Intracerebroventricular infusion of a triglyceride emulsion leads to both direct in hypothalamus and Brockmann bodies. PLoS ONE 8: e59507.
13. Marty N, Dallaporta M, Thorens B (2007) Brain glucose sensing, counter-regulation, and energy homeostasis. Physiology 22: 241–251.
14. Polakof S, Mommens TP, Søegård JL (2011). Glucosensing and glucose homeostasis from fish to mammals. Comp Biochem Physiol B 160: 125–149.
15. Schrama JW, Saravanan S, Søegård JL, Moon TW (2012) Glucose metabolism in fish: a review. J Comp Physiol B 182: 1015–1045.
16. Rasmussen RS, Ostenfeld TH, Roenshold B, McLean E (2000) Manipulation of dietary nutrient composition affects digestible energy utilisation for growth: a study of Nile tilapia (Oreochromis niloticus) and a literature comparison across fish species. Brit J Nutr 108: 277–289.
25. Saravanan S, Geurden I, Figueredo-Silva AC, Kaushik S, Verreth JAJ, et al. (2015) Voluntary feed intake in rainbow trout is regulated by diet-induced differences in oxygen use. J. Nutr. 145: 781–787.
26. Jacobson KA, Gao EZG (2006) Adrenergic receptors as therapeutic targets. Nat Rev Drug Discov 5: 247–264.
27. Bernier NJ, Peter RE (2001) Appetite-suppressing effects of urotensin I and corticotropin-releasing hormone in goldfish (Carassius auratus). Neuropeptides 35: 247–264.
28. Dindia L, Faught E, Leonenko Z, Thomas R, Vijayan MM (2013) Rapid cortisol signaling in response to acute stress involves changes in plasma membrane order in rainbow trout liver. Am J Physiol Endocrinol Metab 304: E1157–E1166.
29. Cox BF, Perrone MH, Weisel GE, Greenland BD, Colussi EJ, et al. 1997. Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocin-treated rats. J Cardiovasc Pharmacol 29: 417–426.
30. Milligan CL (2003) A regulatory role for cortisol in muscle glycogen metabolism in rainbow trout Oncorhynchus mykiss Walbaum. J Exp Biol 206: 3167–3173.
31. Polakof S, Miguez JM, Soengas JL (2008) Dietary carbohydrates induce changes in glucosensing capacity and food intake in rainbow trout. Am J Physiol Regul Integr Comp Physiol 295: R478–R489.
32. Conde-Sieira M, Alvarez R, Lopez-Pattino MA, Miguez JM, Flik G, et al. (2013) ACTH-stimulated cortisol release from head kidney of rainbow trout is modulated by glucose concentration. J Exp Biol 216: 554–567.
33. De Pedro N, Pinillos ML, Valenciano AI, Alonso-Bedate M, Delgado MJ (1998) Inhibitory effect of serotonin on feeding behavior in goldfish: involvement of CRF, Peptides 19: 505–511.
34. Geslin M, Auperin B (2004) Relationship between changes in mRNAs of the glucosensing function of hypothalamus and hindbrain in rainbow trout subjected to hyperglycemic or hypoglycemic conditions. J Comp Physiol A 194: 829–839.
35. Ducasse-Cabanot S, Zambonino-Infante J, Richard N, Medale F, Corraze G, et al. (2004) Relationship between changes in mRNAs of the glucosensing function of hypothalamus and hindbrain in rainbow trout subjected to hyperglycemic or hypoglycemic conditions. J Comp Physiol A 194: 829–839.
36. Velasco-Santamaria YM, Korngarl B, Madsen SS, Bjerregaard P (2012) Beadfrate, a lipid/lowering pharmaceutical, a potential endocrine disruptor in male zebrafish (Danio rerio). Aquat Toxicol 105: 107–118.
37. Martinez-Rubio L, Wadsworth S, Gonzalez Vecino JL, Bell JG, Tocher DR (2013) Effects of dietary digestible energy content on expression of genes of lipid metabolism and LC-PUFA biosynthesis in liver of Atlantic salmon (Salmo salar L.). Aquaculture 384: 387–94. 38. Kreitzmann-Andermahr I, Suarez P, Jennings R, Evers N, Braban G (2010) GH/GH-1 regulation in obesity-mechanisms and practical consequences in children and adults. Horm Res Paediatr 73: 153–160.
39. Watt MJ, Holmes AG, Steinberg GR, Mesa JL, Kemp BE, et al. (2004) Reduced plasma FFA availability increases net triacyl-glycerol degradation, but not GAPAT or HSL, activity, in human skeletal muscle. Am J Physiol Endocrinol Metab 287: E120–E127.
40. Quabble HJ, Lyucks AS, Lage M, Schwartz C (1983) Growth hormone, cortisol, and glucagon concentrations during plasma free fatty acid depression: different effects of niacin and an adenosine derivative (BM 11.109). J Clin Endocrinol Metab 57: 410–414.
41. Albalat A, Gomez-Requeni P, Rojas P, Medale F, Kaushik S, et al. (2005) Expression of corticotropin-releasing factor and urotensin I in the preoptic area of the hypothalamus and hindbrain of rainbow trout. J. Exp. Biol. 214, 3887–3894.
42. Conde-Sieira M, Librán-Pérez M, López-Pattino MA, Miguez JM, Soengas JL (2011) CRF treatment induces a readjustment in glucosensing capacity in the hypothalamus and hindbrain of rainbow trout. J. Exp. Biol. 214, 3887–3894.
43. Bernier NJ, Craig PM (2005) CRF-related peptides contribute to stress response and regulation of appetite in hypoxic rainbow trout. Am J Physiol Regul Integr Comp Physiol 289: R982–R990.
44. Conde-Sieira M, Librán-Pérez M, López-Pattino MA, Miguez JM, Soengas JL (2011) CRF treatment induces a readjustment in glucosensing capacity in the hypothalamus and hindbrain of rainbow trout. J. Exp. Biol. 214, 3887–3894.
45. Bernier NJ, Alderman SL, Brazil ES, Bernier NJ, Craig PM (2005) CRF-related peptides contribute to stress response and regulation of appetite in hypoxic rainbow trout. Am J Physiol Regul Integr Comp Physiol 289: R982–R990.
46. Leach GJ, Taylor MH (1908) The role of cortisol in stress-induced metabolic changes in Fundulus heteroclitus. Gen Comp Endocrinol 42: 219–227.
47. Tripathi G, Vemula P (2003) Pathway-specific response to cortisol in the metabolism of catfish. Comp Biochem Physiol B 136: 463–471.
48. Donou C, Leclair J, Trudeau VL, Moon TW (2006) Corticotropin-releasing factor and neuropeptide Y mRNA levels are modified by glucocorticoids in rainbow trout, Oncorhynchus mykiss. Gen Comp Endocrinol 146: 126–135.
49. Conde-Sieira M, Librán-Pérez M, López-Pattino MA, Miguez JM, Soengas JL (2011) CRF treatment induces a readjustment in glucosensing capacity in the hypothalamus and hindbrain of rainbow trout. J. Exp. Biol. 214, 3887–3894.
50. Bernier NJ, Craig PM (2005) CRF-related peptides contribute to stress response and regulation of appetite in hypoxic rainbow trout. Am J Physiol Regul Integr Comp Physiol 289: R982–R990.
51. Bernier NJ, Alderman SL, Brazil ES, Bernier NJ, Craig PM (2005) CRF-related peptides contribute to stress response and regulation of appetite in hypoxic rainbow trout. Am J Physiol Regul Integr Comp Physiol 289: R982–R990.
52. Harmon JS, Rüenits LM, Sheridan MA (1993) Glucagon and insulin regulate lipolysis in trout liver by altering phosphorylation in triacylglycerol lipase. Am J Physiol Endocrinol Metabol Physiol 263: R255–R260.
53. O’Connor PK, Reich B, Sheridan MA (1993) Growth hormone stimulates hepatic lipid mobilization in rainbow trout, Oncorhynchus mykiss. J Comp Physiol B 163: 427–431.
54. Fabriti E, Capuzzo A, Moon TW (1998) The role of circulating catecholamines in the regulation of fish metabolism: An overview. Comp Biochem Physiol C 120: 177–192.
55. Albalat A, Gómez-Requeni P, Rojas P, Medale F, Kaushik S, et al. (2005) Nutritional and hormonal control of lipolysis in isolated gilthead seabream (Sparus aurata) adipocytes. Am J Physiol Regul Integr Comp Physiol 299: R259–R265.
56. Sangiao-Alvarellos S, Arjona HF, Miguez JM, Martin del Rio MP, Soengas JL, et al. (2006) Growth hormone and prolactin actions on aromatization and energy metabolism of gilthead sea bream (Sparus aurata). Comp Biochem Physiol A 144: 491–500.